Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 641-647

  Kim, Byung Su ^a,b   Bae, Eunkyung ^a   Kim, Young Ju ^a   Ahn, Kwang Sung ^a   Park, Juwon ^a   Rhee, Ji Young ^a,b   Lee, Young Yiul ^c   Kim, Youngsoo ^a   Lee, Dongsoon ^a   Kim, Byoung Kook ^a,b   Yoon, Sung Soo ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; SK 7041 (glivec, histone deacetylase inhibitor); STI571 (gleevec, imatinib)

Indexed keywords

CASPASE; CYCLIN B1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; HISTONE DEACETYLASE INHIBITOR; IMATINIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; SK 7041; TRICHOSTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

AMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIPHENYL COMPOUNDS; CELL CYCLE; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HISTONE DEACETYLASES; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; PYRIMIDINES;

EID: 34548299792     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280761a8a     Document Type: Article

References (14)

1. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44:879-894.
2. Chalandon Y, Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005; 90:949-968.
3. Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol 2006; 83:289-293.
4. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006; 57:145-164.
5. Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S, et al. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 2006; 106:1188-1196.
6. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003; 63:5126-5135.
7. Goldman B. Combinations of targeted therapies take aim at multiple pathways. J Natl Cancer Inst 2003; 95:1656-1657.
8. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003; 88:853-863.
9. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999; 9:171-174.
10. WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. Br J Haematol 2003; 123:34-44.
11. Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 2004; 10:5271-5281.
12. Lanza F, Bi S. Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells 1995; 13:445-452.
13. Rangatia J, Bonnet D. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 2006; 20:68-76.
14. Baghdassarian N, Ffrench M. Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies. Hematol Cell Ther 1996; 38:313-323.